The number of VTEs was lower in the rivaroxaban group compared to placebo (6% versus 8.8%) but did not reach statistical significance.
← all excerpts
Incidence, Therapy, and Bleeding Risk-Cancer- Associated Thrombosis in Patients with Glioblastoma.
1
—
—